Login
Companies $NKTX
$1.21 +$0.00 (0.0%) After hours
Nkarta, Inc. logo

Nkarta, Inc.

nkartatx.com

What Do They Do?

Develops off-the-shelf engineered natural killer cell therapies for people with autoimmune diseases.

How Are They Changing?

Since the FY2025 annual report
Latest quarter: Q3 FY2026, the three months to Sep 30, 2026
Net income
▼ −53% (Loss)
vs −$21.7M in Q3 FY2025

From cancer to autoimmune disease The older report described engineered natural killer cell therapies for cancer, including candidates for blood cancers and tumor targets. The latest report focuses on autoimmune diseases and says the oncology studies closed enrollment and were deprioritized.

Who Do They Compete With?

Competes with AstraZeneca, Autolus, Bristol-Myers Squibb, Cabaletta, Cartesian, Gilead, iCell, Juventas, JW Therapeutics, Kyverna, Miltenyi, Novartis, Roche, Rui Therapeutics, Synthekine, Adicet, Allogene, Artiva, Atara, and CRISPR Therapeutics

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Premium Feature

This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.

Premium includes:

  • Unlimited historical financial data
  • Advanced analytics and insights
  • Priority support